AndrewAdam BernDavisMD

Oncology • Florissant, MO

Physician

Join to view full profile

Dr. Davis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Davis' full profile

Already have an account?

Office
1255 Graham Rd
# Dv
Florissant, MO 63031
Phone+1 800-647-2098

Fax+1 314-362-3192

Education & Training

McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2014 - 2017
Northwestern University The Feinberg School of MedicineClass of 2014

Certifications & Licensure

IL State Medical License 2017 - 2026
MO State Medical License 2020 - 2025
IA State Medical License 2014 - 2021
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
Bryan P Schneider, Fengmin Zhao, Tarah J Ballinger, Sofia F Garcia, Fei Shen
Journal of Clinical Oncology. 2024-08-20
Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells ...
Qiang Zhang, Zheng Cai, Lorenzo Gerratana, Andrew A Davis, Paolo D'Amico
Clinical Cancer Research. 2024-08-15
1 citations
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Lorenzo Gerratana, Masha Kocherginsky, Andrew A Davis, Paolo D'Amico, Carolina Reduzzi
The Oncologist. 2024-02-02

Lectures

A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment.
2019 ASCO Annual Meeting - 6/1/2019
Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Guardant Health and Washington University to Present Study at 2024 ASCO Meeting Highlighting Utility of ctDNA to Address Racial Inequities in the Use of Targeted Therapies and Enrollment in Clinical TrialsJune 3rd, 2024